Multi-chip Liver-12 (MPS-LC12) Plates by CN Bio
Multi-chip Liver-12 consumable plates from CN Bio enable the advanced culture of 12 human 3D liver microtissues under perfusion/plate. Each microtissue recapitulates the functionality and microarchitecture of the human liver to accurately predict drug responses.
Multi-chip Liver-12 (MPS-LC12) plate
Receive your quote directly from the manufacturer.
Multi-chip Liver-12 (MPS-LC12) consumable plates are compatible with PhysioMimix™ Single, and Multi-organ Systems. Arranged in a multi-well format, each plate features 12 independent chips that provide the optimal cell culture environment for primary human hepatocytes and non-parenchymal cells for up to 4 weeks.
During experiments, embedded three-dimensional (3D) scaffolds are continually perfused by oxygen and nutrients to create microtissues that recapitulate human liver functionality and microarchitecture. Following exposure to drug treatment large recoverable volumes of microtissue and culture media enable users to unlock deep mechanistic insights into drug mechanism of action for more informed decision making.
Validated applications for Liver-12 plates include:
- Liver disease modelling: e.g. NAFLD/NASH, Hepatitis B, Breast cancer liver metastasis
- Toxicology: drug-induced liver injury in the presence of absence of liver disease
- ADME: drug metabolism and hepatic clearance
- Pharmacology
- Immuno-oncology
- Drug repurposing
Liver-12 plates are:
- Suitable for organoids, spheroids, iPSCs, primary cells, immortalized cell lines and precision-cut tissue slices
- For use with all CN Bio’s PhysioMimix™ Single and Multi-organ Systems
- Designed to support users transitioning from 2D cell culture into 3D microtissues via a familiar open-well plate-based format
- PDMS-free, reducing non-specific binding for non-biased assessment of drug responses
Contact CN Bio for more information.
Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities
This application note from CN Bio assesses whether a microphysiological system (MPS), also known as Organ-on-a-Chip (OOC), in vitro liver model could be used to understand the detailed mechanistic aspects of liver toxicity.
Human liver microphysiological system for studying acute and chronic drug-induced liver toxicity in vitro
The liver is one of the organs most susceptible to drug toxicity and drug induced liver injury (DILI). DILI is a major cause of drug attrition, with more than 750 FDA approved drugs known to have a degree of DILI risk. There are a number of strategies to de-risk DILI in drug discovery and, in recent years, focus has turned to human in vitro 3D liver models to better predict DILI in early and pre-clinical development. These models culture primary human liver cells, often in co-cultures, in a physiologically relevant environment allowing them to stay functional for extended periods of time. This application assesses whether a microphysiological system (MPS), also known as Organ-on-a-Chip (OOC), in vitro liver model could be used to understand the detailed mechanistic aspects of liver toxicity.
Comparing an <i>in vitro</i> organ-on-chip model of non-alcoholic steatohepatitis to murine models and liver tissue from patients
In this poster, CN BIO compares an in vitro organ-on-chip model of non-alcoholic steatohepatitis to murine models and liver tissue from patients.
Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury
In this application note, CN BIO discusses how they developed a fully human perfused in vitro NAFLD model, utilising primary human hepatocytes (PHH) cultured in 3D to mimic the liver microarchitecture.
Is your *in vitro* toolbox as cutting edge as your portfolio of drug modalities?
In this presentation, find out how organ-on-a-chip (OOC) technology can provide robust and reproducible data that is predictive of the human response. Explore insights from the marketplace as CN Bio CEO, Paul Brooks, details what the market wants, how OOC technology is currently being used in the drug discovery pipeline, and how to address the current challenges of implementing OOC into your workflows.
Plus, Anthony Berger, Field Application Scientist at CN Bio, describes the rapidly changing field of drug modalities and introduces the portfolio of PhysioMimix™ OOC Microphysiological Systems and its applications in drug discovery. Audrey Dubourg, PhysioMimix™ Product Manager, provides further insight into the system and hints at the exciting future developments within CN Bio in this field.
This talk was presented at SLAS2023.
Organ-on-a-chip provides preclinical safety toxicologists with the tools to combat drug attrition
Learn how organ-on-a-chip technology is aiding toxicologists in de-risking drug-induced liver injury by providing human-specific safety data
CN Bio extends microphysiological system portfolio with PhysioMimix single-organ higher throughput system
The PhysioMimix HT system has been designed to increase productivity, cost-effectiveness and data robustness
